Streamline for QRxPharma

By Dylan Bushell-Embling
Tuesday, 05 August, 2008

The US Food and Drug Administration has granted approval to QRxPharma's [ASX: QRX] streamlined Phase III development plan for lead candidate Q8003IR.

This approval means that QRxPharma will be required to conduct only two Phase III trials for New Drug Agreement [NDA] filing. No additional pharmacology, toxicology or long term clinical safety studies will be required.

Q8003IR is an immediate release dual-opioid containing both morphine and oxycodone, and is intended to be used in the management of moderate to severe pain.

The FDA did make some changes to QRxPharma's proposal, but according to company representatives these changes were minimal.

Content from other channels on our network

Health Star Ratings set to become regulated in Australia and NZ

Fast detection of food contamination using enhanced AI tool

Abattoir safety program in WA raises more awareness

Closing the loop with food packaging made from fish skin waste

Electric trucks hit the road to deliver beer in Perth

Liquid metal to 'harvest' clean hydrogen from water

Epson makes progress with sustainability plans and initiatives in Australia and New Zealand

Sustainable wastewater treatment achieved for urban areas

'Brownfielding' increases to meet metal demand

NSW to exceed energy storage targets

Cyber risk is rising faster than Australian manufacturers can respond

Fortescue commissions first battery electric locomotives

Electric actuation: a gamechanger for upstream processes

Government seeks input on wind and transmission infrastructure

Additive manufacturing unlocks power for space and defence missions

Streamline for QRxPharma

Noxopharm says paper reveals science behind its immune system platform

Neurosensing/neurostimulation implants session to be held on Monday

argenx and Monash University partner against autoimmune diseases

Content from other channels on our network